Publications by authors named "A Troeger"
Article Synopsis
- Scientists are working on new cancer treatments called immunotherapies, especially using CAR T cells, which have shown great results for kids with a type of leukemia.
- When kids' leukemia comes back or doesn’t respond to regular treatments, they need a different kind of temporary treatment called bridging therapy before getting CAR T cells.
- A group of doctors in Europe is trying to create guidelines for this bridging therapy to make sure it’s more effective and consistent for all kids with this kind of cancer.
Objectives: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCD and bone marrow from an HLA-matched sibling is currently the standard of care. Haploidentical HSCT from a family donor with a TCR αβ/CD19 depleted graft (T-haplo) is an increasingly successful alternative, which requires the generation of G-CSF stimulated peripheral stem cell (PBSC) from haploidentical relatives. These sickle cell trait (SCT) donors reported to develop SCD-related complications in conditions of severe stress.
View Article and Find Full Text PDFBackground: Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in the Comprehensive Cancer Center Ostbayern (CCCO) from 2019 to 2021.
Methods And Results: In total, 251 patients were included.
Article Synopsis
- Metastatic disease is when cancer spreads and is a big problem for kids with medulloblastoma, a type of brain cancer, making it really hard to treat.
- Researchers found that a specific protein called Rac1 helps tumors move, so stopping it could help treat cancer and prevent it from spreading.
- They tested some existing medicines that target Rac1 and found that one called Pictilisib works really well to stop the movement of medulloblastoma cells, which is a good sign for future treatments.
Purpose: Intracranial germ cell tumors (iGCT) comprise germinoma and non-germinoma. Their diagnosis predominantly relies on biopsy as only one-fifth of patients present with elevated biomarkers (AFP/ß-HCG) in serum or cerebrospinal fluid (CSF). MicroRNAs (miR/miRNA) have emerged as non-invasive biomarkers in extracranial GCT and may potentially facilitate non-invasive diagnosis in iGCT.
View Article and Find Full Text PDF